Coherus Presents Positive Phase 2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2024 ASCO GI Cancers Symposium
January 18, 2024 16:05 ET
|
Coherus BioSciences, Inc.
– Data demonstrate early activity with casdozokitug/atezolizumab/bevacizumab; 38% objective response rate including three complete responses – – Data support casdozo as a promising novel...
Coherus BioSciences Management to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 03, 2024 09:00 ET
|
Coherus BioSciences, Inc.
REDWOOD CITY, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” Nasdaq: CHRS), today announced that senior management will present at the upcoming 42nd Annual J.P....
Coherus Announces U.S. Launch of LOQTORZI™
January 02, 2024 08:29 ET
|
Coherus BioSciences, Inc.
– Launch of LOQTORZI offers first and only FDA-approved treatment for NPC in all lines of therapy – – Indicated in combination with chemotherapy for 1st line treatment and as monotherapy for patients...
Coherus Announces FDA Approval of UDENYCA ONBODY™, a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv
December 26, 2023 16:01 ET
|
Coherus BioSciences, Inc.
– Innovative design enables five-minute pegfilgrastim delivery time – – Unique, automatic, retractable needle mechanism engineered to maximize safety and comfort for cancer patients receiving...
Coherus Announces Updated NCCN Clinical Practice Guidelines Positioning LOQTORZI™ (toripalimab-tpzi) as Preferred Category 1 Regimen for First-Line Treatment of Cancer of the Nasopharynx
December 11, 2023 08:30 ET
|
Coherus BioSciences, Inc.
– NCCN Guidelines recommend LOQTORZI as the only Preferred Category 1 treatment option in first-line treatment for adults with metastatic or recurrent locally advanced NPC in combination with...
Coherus and Junshi Biosciences Announce Publication of Positive Final Overall Survival Results of JUPITER-02, a Phase 3 Trial Evaluating LOQTORZI™ (toripalimab-tpzi) as Treatment for Nasopharyngeal Carcinoma, in the Journal of the American Medical Association
November 28, 2023 11:16 ET
|
Coherus BioSciences, Inc.
– Final overall survival analysis of the JUPITER-02 trial shows first-line treatment with LOQTORZI plus chemotherapy significantly prolongs survival in patients with recurrent or metastatic NPC...
Coherus BioSciences Reports Third Quarter 2023 Financial Results and Business Highlights
November 06, 2023 16:07 ET
|
Coherus BioSciences, Inc.
– Net revenue rose 27% from prior quarter to $74.6 million –– CIMERLI® net sales increased 50% to $40 million compared to prior quarter –– LOQTORZI™ now approved with launch planned for the first...
Coherus BioSciences to Report Third Quarter 2023 Financial Results on November 6, 2023
October 30, 2023 18:00 ET
|
Coherus BioSciences, Inc.
REDWOOD CITY, Calif., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) today announced that its third quarter 2023 financial results will be released after...
Coherus and Junshi Biosciences Announce FDA Approval of LOQTORZI™ (toripalimab-tpzi) in All Lines of Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)
October 27, 2023 15:07 ET
|
Coherus BioSciences, Inc.
– LOQTORZI is the first and only FDA-approved treatment for NPC – – Indicated in combination with chemotherapy for 1st line treatment and as monotherapy for patients with disease progression on or...
Coherus Announces Three Presentations at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
September 27, 2023 09:10 ET
|
Coherus BioSciences, Inc.
REDWOOD CITY, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS), today announced the presentation of three abstracts from its innovative immuno-oncology...